Please visit answersincme.com/FPV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the diagnosis and pharmacological management of Lennox-Gastaut syndrome (LGS), and is joined by a patient advocate to discuss the impact of LGS on patients and their families. Upon completion of this activity, participants should be better able to: Recognize the clinical impact of LGS on the lives of patients with the disease and their families; Outline strategies to accurately diagnose LGS in children and adults; and Describe the pharmacological treatment options available for patients with LGS.

Please visit answersincme.com/WZP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses foundational elements of this emerging technology and its implications in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians’ and patients’ perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Please visit answersincme.com/DDF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in advanced gastric cancer discuss the rationale for testing for HER2 status in patients with advanced gastric cancer and how to optimize care based on the latest clinical evidence. Upon completion of this activity, participants should be better able to: Recognize the rationale for testing for HER2 status in patients with pretreated advanced gastric cancer; Translate the latest clinical evidence on testing to guide selection of HER2-targeted treatments for advanced gastric cancer; and Outline practical multidisciplinary approaches to optimize personalized care of patients with previously treated HER2-positive advanced gastric cancer to enhance health-related quality of life.

Please visit answersincme.com/XXZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human papillomavirus (HPV) vaccination in males to reduce the burden of HPV-related cancers. Upon completion of this activity, participants should be better able to: Recognize the rationale for vaccination against HPV infection in the male population; Describe the clinical evidence for the guideline-recommended HPV vaccines; and Outline strategies to enhance acceptance of HPV vaccination among the male population.

Please visit answersincme.com/PKW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cardiology discusses guideline and treatment updates for the management of hypertrophic cardiomyopathy, and the clinical implications of recent data on novel cardiac myosin inhibitors. Upon completion of this activity, participants should be better able to: Outline the latest guideline updates for diagnosis and treatment of obstructive HCM; Review strategies to facilitate the early diagnosis of obstructive HCM; and Recognize the clinical significance of the latest data on cardiac myosin inhibitors for the treatment of obstructive HCM.

Please visit answersincme.com/MVB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology and a patient advocate discuss strategies to optimize care for patients with metastatic breast cancer using antibody-drug conjugates. Upon completion of this activity, participants should be better able to: Identify the rationale for targeted antibody-drug conjugates (ADCs) in the treatment of patients with metastatic breast cancer (mBC); Review strategies to enhance safety of the available ADCs for the treatment of mBC; and Outline patient-focused strategies to optimize the use of ADCs in appropriate patients with mBC.

Please visit answersincme.com/TAR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the integration of perioperative immunotherapy-based regimens for the treatment of resectable non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Recognize the rationale for the use of neoadjuvant followed by adjuvant immunotherapy-based regimens in patients with resectable NSCLC; Describe current evidence on the use of neoadjuvant plus adjuvant immunotherapy in patients with resectable NSCLC; and Outline practical strategies to integrate neoadjuvant plus adjuvant immunotherapy-based regimens into the treatment plan for appropriate patients with resectable NSCLC.

Please visit answersincme.com/PQD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in squamous cell carcinoma of the head and neck (SCCHN) discusses the clinical potential of antagonists of inhibitor of apoptosis proteins (IAPs) for unresected, locally advanced SCCHN. Upon completion of this activity, participants should be better able to: Identify the rationale for investigating the use of antagonists of inhibitor of apoptosis proteins (IAPs) in the treatment of unresected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN); Discuss the latest efficacy and safety data for emerging IAP antagonists for the treatment of unresected LA SCCHN; and Outline clinical considerations for future use of IAP antagonists in unresected LA SCCHN.

Please visit answersincme.com/HRM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cancerous lymphoma discusses EZH2 and EZH1 inhibitors for the management of relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas. Upon completion of this activity, participants should be better able to: Describe the rationale for exploring EZH 2 and EZH1 inhibitors for the management of relapsed or refractory (R/R) B-cell and T-cell non-Hodgkin lymphomas (NHLs); Explain the mechanism of action (MOA) of EZH2 and EZH1 inhibition; and Review the clinical profiles of approved and emerging EZH2 and EZH1 inhibitors for R/R B-cell and T-cell NHLs.

Please visit answersincme.com/GHX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women’s health discusses improving human papillomavirus (HPV) vaccination uptake among lesbian, gay, bisexual, transgender, and queer (LGBTQ+) individuals. Upon completion of this activity, participants should be better able to: Identify the clinical impact of low uptake of HPV vaccination among LGBTQ+ individuals; Review the clinical profiles and suggested administration of guideline-recommended HPV vaccines; and Outline patient-centered strategies to enhance acceptance of HPV vaccination among LGBTQ+ individuals.

Please visit answersincme.com/GXJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in cutaneous oncology discusses neoadjuvant immunotherapy in resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; Outline evidence-based, patient-centered strategies to select an appropriate treatment approach for patients with resectable CSCC; and Review strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.

Please visit answersincme.com/XHR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in follicular lymphoma discuss the integration of bispecific antibodies into the treatment of relapsing/refractory follicular lymphoma. Upon completion of this activity, participants should be better able to: Review the clinical profiles of novel CD20 x CD3 bispecific antibodies (BsAbs) for relapsing/refractory follicular lymphoma (R/R FL); Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL; and Outline evidence-based multidisciplinary strategies for optimal integration of BsAbs in the treatment plans of patients with R/R FL.

Please visit answersincme.com/GXD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gynecologic oncology discusses the evolving role of antibody-drug conjugates (ADCs) in HER2-expressing solid tumors. Upon completion of this activity, participants should be better able to: Recognize the role of human epidermal growth factor receptor 2 (HER2) in the pathogenesis of various solid tumors; Describe strategies to optimize HER2 biomarker testing in patients with various solid tumors; Review the evidence for HER2-directed antibody-drug conjugates (ADCs) that have demonstrated benefits in multiple types of HER2-expressing solid tumors; and Outline practical approaches to enhance outcomes for patients receiving HER2-directed ADCs for various solid tumors.

Please visit answersincme.com/DWQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in genetics discusses effective communication and treatment strategies for patients with phenylketonuria (PKU), including a patient’s perspective. Upon completion of this activity, participants should be better able to: Recognize the challenges adult patients with PKU face that impact quality of life; Discuss the impact of PKU on executive functioning in adult patients with PKU; and Practice effective patient-centered strategies to optimize care for adults with PKU.

Please visit answersincme.com/NRW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the optimization of care for patients with relapsed/refractory follicular lymphoma (R/R FL) and treatment with bispecific antibodies (BsAbs). Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BsAbs in patients with R/R FL; Review the clinical profiles of novel anti-CD20 × CD3 BsAbs for R/R FL; and Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL.

Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the rationale for the use of IL-36 receptor inhibitors in treating GPP; and Describe the clinical profiles of novel approved and emerging IL-36 receptor inhibitors for the treatment of GPP.

Please visit answersincme.com/TXC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the unmet therapeutic needs in patients with chronic obstructive pulmonary disease (COPD) and the rationale for targeting Type 2 inflammation. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in patients with COPD; Identify patients with COPD who are at high risk of exacerbations despite receiving standard therapies; and Recognize the rationale for targeting Type 2 inflammation for the treatment of COPD.

Please visit answersincme.com/EFR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in liver disease discusses management of unresectable hepatocellular carcinoma through multiple lines of therapy. Upon completion of this activity, participants should be better able to: Identify clinical signs of progression on treatment for unresectable hepatocellular carcinoma (HCC) to enhance timely use of a sequential therapy; Describe the clinical impact of tyrosine kinase inhibitors for the real-world treatment of unresectable HCC; and Outline real-world clinical strategies to maximize the long-term treatment plan for patients with unresectable HCC through multiple lines of therapy.

Please visit answersincme.com/ADB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the rationale and clinical data for incorporating neoadjuvant immunotherapy into the treatment of resectable cutaneous squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for incorporating neoadjuvant immunotherapy in the treatment of resectable CSCC; Describe the clinical impact of neoadjuvant immunotherapy in treating resectable CSCC; and Review multidisciplinary team strategies to enhance outcomes for patients with resectable CSCC who may be candidates for neoadjuvant immunotherapy.